641
Views
4
CrossRef citations to date
0
Altmetric
Drug Evaluation

Pharmacokinetic drug evaluation of abemaciclib for advanced breast cancer

, , , , , , & show all
Pages 85-91 | Received 20 Aug 2018, Accepted 13 Dec 2018, Published online: 05 Jan 2019

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Vittorio Gebbia, Maria Rosaria Valerio, Alberto Firenze & Paolo Vigneri. (2020) Abemaciclib: safety and effectiveness of a unique cyclin-dependent kinase inhibitor. Expert Opinion on Drug Safety 19:8, pages 945-954.
Read now

Articles from other publishers (3)

Ariana Soledad Poetto, Bianca Posocco, Martina Zanchetta, Sara Gagno, Marco Orleni, Giovanni Canil, Martina Alberti, Fabio Puglisi & Giuseppe Toffoli. (2022) “A new LC-MS/MS method for the simultaneous quantification of abemaciclib, its main active metabolites M2 and M20, and letrozole for therapeutic drug monitoring”. Journal of Chromatography B 1207, pages 123403.
Crossref
Disha Thakkar & Abhijeet S. Kate. (2020) Update on metabolism of abemaciclib: In silico , in vitro , and in vivo metabolite identification and characterization using high resolution mass spectrometry . Drug Testing and Analysis 12:3, pages 331-342.
Crossref
Emanuel Raschi & Fabrizio De Ponti. (2019) Strategies for Early Prediction and Timely Recognition of Drug-Induced Liver Injury: The Case of Cyclin-Dependent Kinase 4/6 Inhibitors. Frontiers in Pharmacology 10.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.